456 related articles for article (PubMed ID: 33382703)
1. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
Hsieh MH; Kao TY; Hsieh TH; Kao CC; Peng CY; Lai HC; Chuang PH; Kao JT
PLoS One; 2020; 15(12):e0244293. PubMed ID: 33382703
[TBL] [Abstract][Full Text] [Related]
2. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Casadei Gardini A; Marisi G; Scarpi E; Scartozzi M; Faloppi L; Silvestris N; Masi G; Vivaldi C; Brunetti O; Tamberi S; Foschi FG; Tamburini E; Tenti E; Ricca Rosellini S; Ulivi P; Cascinu S; Nanni O; Frassineti GL
Expert Opin Pharmacother; 2015; 16(18):2719-25. PubMed ID: 26513009
[TBL] [Abstract][Full Text] [Related]
4. Treatment with metformin is associated with a prolonged survival in patients with hepatocellular carcinoma.
Schulte L; Scheiner B; Voigtländer T; Koch S; Schweitzer N; Marhenke S; Ivanyi P; Manns MP; Rodt T; Hinrichs JB; Weinmann A; Pinter M; Vogel A; Kirstein MM
Liver Int; 2019 Apr; 39(4):714-726. PubMed ID: 30663219
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
[TBL] [Abstract][Full Text] [Related]
7. Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
Casadei Gardini A; Scarpi E; Marisi G; Foschi FG; Donati G; Giampalma E; Faloppi L; Scartozzi M; Silvestris N; Bisulli M; Corbelli J; Gardini A; La Barba G; Veneroni L; Tamberi S; Cascinu S; Frassineti GL
Oncotarget; 2016 Mar; 7(12):15243-51. PubMed ID: 26893366
[TBL] [Abstract][Full Text] [Related]
8. Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma.
Jouve JL; Lecomte T; Bouché O; Barbier E; Khemissa Akouz F; Riachi G; Nguyen Khac E; Ollivier-Hourmand I; Debette-Gratien M; Faroux R; Villing AL; Vergniol J; Ramee JF; Bronowicki JP; Seitz JF; Legoux JL; Denis J; Manfredi S; Phelip JM;
J Hepatol; 2019 Sep; 71(3):516-522. PubMed ID: 31125576
[TBL] [Abstract][Full Text] [Related]
9. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
10. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Labenz C; Prenosil V; Koch S; Huber Y; Marquardt JU; Schattenberg JM; Galle PR; Weinmann A; Wörns MA
Dig Dis; 2018; 36(1):78-88. PubMed ID: 28675895
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis.
McNamara MG; Slagter AE; Nuttall C; Frizziero M; Pihlak R; Lamarca A; Tariq N; Valle JW; Hubner RA; Knox JJ; Amir E
Eur J Cancer; 2018 Dec; 105():1-9. PubMed ID: 30384012
[TBL] [Abstract][Full Text] [Related]
12. Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.
Takada H; Kurosaki M; Nakanishi H; Takahashi Y; Itakura J; Tsuchiya K; Yasui Y; Tamaki N; Takaura K; Komiyama Y; Higuchi M; Kubota Y; Wang W; Okada M; Enomoto N; Izumi N
PLoS One; 2018; 13(6):e0198812. PubMed ID: 29912922
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.
Tanaka T; Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Oncology; 2020; 98(9):621-629. PubMed ID: 32434180
[TBL] [Abstract][Full Text] [Related]
15. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
[TBL] [Abstract][Full Text] [Related]
16. Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Kuo YH; Wang JH; Hung CH; Rau KM; Wu IP; Chen CH; Kee KM; Hu TH; Lu SN
J Gastroenterol Hepatol; 2017 Dec; 32(12):1975-1981. PubMed ID: 28295594
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
18. The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib.
Caputo F; Dadduzio V; Tovoli F; Bertolini G; Cabibbo G; Cerma K; Vivaldi C; Faloppi L; Rizzato MD; Piscaglia F; Celsa C; Fornaro L; Marisi G; Conti F; Silvestris N; Silletta M; Lonardi S; Granito A; Stornello C; Massa V; Astara G; Delcuratolo S; Cascinu S; Scartozzi M; Casadei-Gardini A
PLoS One; 2020; 15(5):e0232449. PubMed ID: 32379785
[TBL] [Abstract][Full Text] [Related]
19. Diabetes worsens the surgical outcomes in cirrhotic patients with hepatocellular carcinoma.
Ting CT; Chen RC; Chen CC; Liu MH; Chu D; Kuo NW
Tohoku J Exp Med; 2012 May; 227(1):73-81. PubMed ID: 22688467
[TBL] [Abstract][Full Text] [Related]
20. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases.
Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK
Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
